Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +20.21%
#2 B3 (Base) B3 (Base) +8.53%
#3 Fake World Assets Fake World Assets +8.14%
#4 Tornado Cash Tornado Cash +6.81%
#5 Geodnet Geodnet +6.39%
#6 OriginTrail OriginTrail +6.25%
#7 Audiera Audiera +5.37%
#8 Storj Storj +5.26%
#9 Pons Pons +5.16%
#10 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +5.02%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
Easywell Biomedicals, Inc. Easywell Biomedicals, Inc.

Easywell Biomedicals, Inc.

1799
Rank in Stocks #20882
Easywell Biomedicals, Inc., together with its subsidiaries, develops,... Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Share Price
$0.96033064
Last synced: 2026-08-21
Market Cap
$119.74M
Change (1 day)
0.67%
Change (1 year)
-33.99%
Country
TW
Trade Easywell Biomedicals, Inc. (1799)

Category

Healthcare
P/E ratio for Easywell Biomedicals, Inc. (1799)
P/E ratio as of 2026 TTM: 0
According to Easywell Biomedicals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Easywell Biomedicals, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 24.32 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.13 -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.